SAVE (Safe Accelerated Venetoclax Escalation): Initial results of a prospective, phase Ib study of venetoclax with an accelerated dose ramp-up in patients with CLL.Jennifer L. Crombie, Matthew S. Davids, Josie Montegaard et al.|Journal of Clinical Oncology|2023Cited by 2
A Phase 2 Study of Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Inhye E. Ahn, Jennifer R. Brown, Yinglu Zhou et al.|Blood|2023Cited by 1
212 | SAVE (SAFE ACCELERATED VENETOCLAX ESCALATION): RESULTS OF A PROSPECTIVE, PHASE Ib STUDY OF VENETOCLAX WITH AN ACCELERATED DOSE RAMP‐UP IN PATIENTS WITH CLLJennifer L. Crombie, Matthew S. Davids, Il Young Ahn et al.|Hematological Oncology|2025Cited by 0